391 related articles for article (PubMed ID: 32970635)
1. CMV viral load kinetics as surrogate endpoints after allogeneic transplantation.
Duke ER; Williamson BD; Borate B; Golob JL; Wychera C; Stevens-Ayers T; Huang ML; Cossrow N; Wan H; Mast TC; Marks MA; Flowers ME; Jerome KR; Corey L; Gilbert PB; Schiffer JT; Boeckh M
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 32970635
[TBL] [Abstract][Full Text] [Related]
2. Mathematical Modeling of Within-Host, Untreated, Cytomegalovirus Infection Dynamics after Allogeneic Transplantation.
Duke ER; Boshier FAT; Boeckh M; Schiffer JT; Cardozo-Ojeda EF
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835098
[TBL] [Abstract][Full Text] [Related]
3. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
Marty FM; Winston DJ; Chemaly RF; Mullane KM; Shore TB; Papanicolaou GA; Chittick G; Brundage TM; Wilson C; Morrison ME; Foster SA; Nichols WG; Boeckh MJ;
Biol Blood Marrow Transplant; 2019 Feb; 25(2):369-381. PubMed ID: 30292744
[TBL] [Abstract][Full Text] [Related]
5. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
Camargo JF; Kimble E; Rosa R; Shimose LA; Bueno MX; Jeyakumar N; Morris MI; Abbo LM; Simkins J; Alencar MC; Benjamin C; Wieder E; Jimenez A; Beitinjaneh A; Goodman M; Byrnes JJ; Lekakis LJ; Pereira D; Komanduri KV
Biol Blood Marrow Transplant; 2018 Apr; 24(4):806-814. PubMed ID: 29217388
[TBL] [Abstract][Full Text] [Related]
6. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.
Chen K; Cheng MP; Hammond SP; Einsele H; Marty FM
Blood Adv; 2018 Aug; 2(16):2159-2175. PubMed ID: 30154125
[TBL] [Abstract][Full Text] [Related]
7. [Ganciclovir treatment failure in adult allogeneic hematopoietic stem cell transplant recipients with cytomegalovirus infection--a single centre experience].
Vejražková E; Hubáček P; Kutová R; Plíšková L; Košťál M; Štěpánová V; Zavřelová A; Radocha J; Malá E; Žák P
Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):160-8. PubMed ID: 26448304
[TBL] [Abstract][Full Text] [Related]
8. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation.
Mori T; Okamoto S; Watanabe R; Yajima T; Iwao Y; Yamazaki R; Nakazato T; Sato N; Iguchi T; Nagayama H; Takayama N; Hibi T; Ikeda Y
Bone Marrow Transplant; 2002 May; 29(9):777-82. PubMed ID: 12040476
[TBL] [Abstract][Full Text] [Related]
9. Impact of CMV therapy with valganciclovir on immune activation and the HIV viral load in semen and blood: an observational clinical study.
Shin LY; Sheth PM; Persad D; Kovacs C; Kain T; Diong C; Su D; Ostrowski M; Raboud JM; Kaul R
J Acquir Immune Defic Syndr; 2014 Mar; 65(3):251-8. PubMed ID: 24091693
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
Li L; Wang Y; Yan CH; Huang XJ
Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
[No Abstract] [Full Text] [Related]
11. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
12. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
Nichols WG; Corey L; Gooley T; Drew WL; Miner R; Huang M; Davis C; Boeckh M
Blood; 2001 Feb; 97(4):867-74. PubMed ID: 11159510
[TBL] [Abstract][Full Text] [Related]
13. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
[TBL] [Abstract][Full Text] [Related]
14. Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis.
Natori Y; Alghamdi A; Tazari M; Miller V; Husain S; Komatsu T; Griffiths P; Ljungman P; Orchanian-Cheff A; Kumar D; Humar A;
Clin Infect Dis; 2018 Feb; 66(4):617-631. PubMed ID: 29020339
[TBL] [Abstract][Full Text] [Related]
15. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
Chawla JS; Ghobadi A; Mosley J; Verkruyse L; Trinkaus K; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Uy GL; Westervelt P; DiPersio JF; Vij R
Transpl Infect Dis; 2012 Jun; 14(3):259-67. PubMed ID: 22093134
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation.
Rayes N; Seehofer D; Schmidt CA; Oettle H; Müller AR; Steinmüller T; Settmacher U; Bechstein WO; Neuhaus P
Transplantation; 2001 Sep; 72(5):881-5. PubMed ID: 11571454
[TBL] [Abstract][Full Text] [Related]
18. CMV viral load in bronchoalveolar lavage for diagnosis of pneumonia in allogeneic hematopoietic stem cell transplantation.
Iglesias L; Perera MM; Torres-Miñana L; Pena-López MJ
Bone Marrow Transplant; 2017 Jun; 52(6):895-897. PubMed ID: 28218754
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Gagelmann N; Ljungman P; Styczynski J; Kröger N
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2101-2109. PubMed ID: 29777868
[TBL] [Abstract][Full Text] [Related]
20. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
